[2]
Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T, A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast cancer research and treatment. 2012 Jun; [PubMed PMID: 22418700]
[3]
Yang Z,Hackshaw A,Feng Q,Fu X,Zhang Y,Mao C,Tang J, Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. International journal of cancer. 2017 Jun 15; [PubMed PMID: 28295308]
[4]
Li D,Ambrogio L,Shimamura T,Kubo S,Takahashi M,Chirieac LR,Padera RF,Shapiro GI,Baum A,Himmelsbach F,Rettig WJ,Meyerson M,Solca F,Greulich H,Wong KK, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7; [PubMed PMID: 18408761]
[5]
Wind S,Schnell D,Ebner T,Freiwald M,Stopfer P, Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clinical pharmacokinetics. 2017 Mar; [PubMed PMID: 27470518]
[6]
Niebecker R,Maas H,Staab A,Freiwald M,Karlsson MO, Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib. CPT: pharmacometrics [PubMed PMID: 30681293]
[7]
Jobe AL,Ahonen KT,Poplin V,Rao S,Mohyuddin GR, Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus. 2018 Jun 14; [PubMed PMID: 30123727]